Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Crizotinib"" wg kryterium: Temat


Tytuł :
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer.
Autorzy :
Shaw AT; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Bauer TM; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
de Marinis F; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Felip E; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Goto Y; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Liu G; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Mazieres J; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Kim DW; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Mok T; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Polli A; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Thurm H; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Calella AM; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Peltz G; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Solomon BJ; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Pokaż więcej
Corporate Authors :
CROWN Trial Investigators
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Nov 19; Vol. 383 (21), pp. 2018-2029.
Typ publikacji :
Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Anaplastic Lymphoma Kinase/*antagonists & inhibitors
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Crizotinib/*therapeutic use
Lactams, Macrocyclic/*therapeutic use
Lung Neoplasms/*drug therapy
Adult ; Aged ; Anaplastic Lymphoma Kinase/genetics ; Antineoplastic Agents/adverse effects ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/mortality ; Crizotinib/adverse effects ; Female ; Humans ; Hyperlipidemias/chemically induced ; Intention to Treat Analysis ; Lactams, Macrocyclic/adverse effects ; Lung Neoplasms/genetics ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Mutation ; Survival Analysis
Czasopismo naukowe
Tytuł :
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Autorzy :
Mok T; State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Shatin, NT, Hong Kong.
Camidge DR; University of Colorado, Denver, USA.
Gadgeel SM; Department of Internal Medicine, Rogel Cancer Center/University of Michigan, Ann Arbor, USA.
Rosell R; Catalan Institute of Oncology, Barcelona, Spain.
Dziadziuszko R; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
Kim DW; Seoul National University Hospital, Seoul, South Korea.
Pérol M; Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.
Ou SI; Chao Family Comprehensive Cancer Center, University of California, Irvine, USA.
Ahn JS; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Shaw AT; Massachusetts General Hospital, Boston, USA.
Bordogna W; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Smoljanović V; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Hilton M; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Ruf T; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Noé J; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Peters S; Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. Electronic address: .
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2020 Aug; Vol. 31 (8), pp. 1056-1064. Date of Electronic Publication: 2020 May 11.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Crizotinib*/therapeutic use
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Anaplastic Lymphoma Kinase/genetics ; Humans ; Progression-Free Survival ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł :
Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib.
Autorzy :
Kaira K; Department of Oncology Clinical Development, Gunma University Graduate School of Medicine, Gunma University Hospital, Gunma, Japan.
Naruse I; Department of Respiratory Medicine, Hidaka Hospital, Gunma, Japan.
Shimizu K; Division of General Thoracic Surgery, Integrative Center of General Surgery, Gunma University Hospital, Gunma, Japan.
Asao T; Big Data Center for Integrative Analysis, Gunma University Initiative for Advance Research, Takasaki, Gunma, Japan.
Pokaż więcej
Źródło :
Journal of cancer research and therapeutics [J Cancer Res Ther] 2020 Jul-Sep; Vol. 16 (4), pp. 919-921.
Typ publikacji :
Case Reports
MeSH Terms :
Adenocarcinoma of Lung/*drug therapy
Carbazoles/*adverse effects
Crizotinib/*adverse effects
Lung Diseases, Interstitial/*chemically induced
Lung Neoplasms/*drug therapy
Piperidines/*adverse effects
Protein Kinase Inhibitors/*adverse effects
Adenocarcinoma of Lung/genetics ; Adenocarcinoma of Lung/pathology ; Aged, 80 and over ; Anaplastic Lymphoma Kinase/genetics ; Carbazoles/therapeutic use ; Crizotinib/therapeutic use ; Humans ; Lung Diseases, Interstitial/genetics ; Lung Diseases, Interstitial/pathology ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Male ; Piperidines/therapeutic use ; Prognosis ; Protein Kinase Inhibitors/therapeutic use
Raport
Tytuł :
Revealing Acquired Resistance Mechanisms of Kinase-Targeted Drugs Using an on-the-Fly, Function-Site Interaction Fingerprint Approach.
Autorzy :
Zhao Z
Bourne PE
Pokaż więcej
Źródło :
Journal of chemical theory and computation [J Chem Theory Comput] 2020 May 12; Vol. 16 (5), pp. 3152-3161. Date of Electronic Publication: 2020 Apr 24.
Typ publikacji :
Journal Article
MeSH Terms :
Anaplastic Lymphoma Kinase/*antagonists & inhibitors
Crizotinib/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Pyrimidines/*pharmacology
Sulfones/*pharmacology
Anaplastic Lymphoma Kinase/genetics ; Anaplastic Lymphoma Kinase/metabolism ; Crizotinib/chemistry ; Humans ; Models, Molecular ; Molecular Structure ; Protein Kinase Inhibitors/chemistry ; Pyrimidines/chemistry ; Sulfones/chemistry
Czasopismo naukowe
Tytuł :
Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study.
Autorzy :
Shimokawa M; Cancer Biostatistics Laboratory, Clinical Research Institute, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. .; Department of Biostatistics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi, 755-8505, Japan. .
Nosaki K; Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.; Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.
Seto T; Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Ohashi K; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Morise M; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Horinouchi H; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Sakakibara J; First Department of Medicine, Hokkaido University Hospital, Hokkaido, Japan.
Murakami H; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Yano S; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Satouchi M; Department of Thoracic Oncology, Hyogo Cancer Center, Hyogo, Japan.
Matsumoto S; Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.
Goto K; Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.
Yoh K; Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.
Pokaż więcej
Źródło :
Trials [Trials] 2020 Mar 30; Vol. 21 (1), pp. 298. Date of Electronic Publication: 2020 Mar 30.
Typ publikacji :
Clinical Trial Protocol; Journal Article
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*drug therapy
Crizotinib/*administration & dosage
Lung Neoplasms/*drug therapy
Protein Kinase Inhibitors/*administration & dosage
Proto-Oncogene Proteins c-met/*genetics
Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Clinical Trials, Phase II as Topic ; Crizotinib/adverse effects ; Disease Progression ; High-Throughput Nucleotide Sequencing ; Humans ; Japan ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Multicenter Studies as Topic ; Mutation ; Protein Kinase Inhibitors/adverse effects
Czasopismo naukowe
Tytuł :
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.
Autorzy :
Huber RM; Division of Respiratory Medicine and Thoracic Oncology, Department of Medicine V, University Hospital of Munich, Thoracic Oncology Centre Munich, German Centre for Lung Research, Munich, Bavaria, Germany. Electronic address: .
Hansen KH; Department of Clinical Oncology, Odense University Hospital, Odense, Denmark.
Paz-Ares Rodríguez L; Medical Oncology Department, University Hospital '12 de Octubre,' Madrid, Spain.
West HL; Thoracic Oncology Program, Swedish Cancer Institute, Seattle, Washington.
Reckamp KL; Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, California.
Leighl NB; Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Tiseo M; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Smit EF; Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, the Netherlands.
Kim DW; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Gettinger SN; Yale Cancer Center, New Haven, Connecticut.
Hochmair MJ; Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna, Austria.
Kim SW; Department of Oncology, Asan Medical Center, Seoul, South Korea.
Langer CJ; University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.
Ahn MJ; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Kim ES; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.
Kerstein D; Millennium Pharmaceuticals, Inc. (wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts.
Groen HJM; University of Groningen and University Medical Center Groningen, Groningen, the Netherlands.
Camidge DR; University of Colorado Cancer Center, Aurora, Colorado.
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2020 Mar; Vol. 15 (3), pp. 404-415. Date of Electronic Publication: 2019 Nov 19.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Crizotinib*/therapeutic use
Lung Neoplasms*/drug therapy
Protein Kinase Inhibitors*/therapeutic use
Anaplastic Lymphoma Kinase/genetics ; Follow-Up Studies ; Humans ; Organophosphorus Compounds ; Pyrimidines
Czasopismo naukowe
Tytuł :
Crizotinib versus chemotherapy: a real-world cost-effectiveness study in China.
Autorzy :
Huang M; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Tian Y; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
He M; Fengling Clinic, Wuhou, Chengdu 610041, China.
Liu J; Fengling Clinic, Wuhou, Chengdu 610041, China.
Ren L; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Gong Y; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Peng F; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Wang Y; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Ding Z; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Wang J; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Zhu J; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Xu Y; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Liu Y; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Li L; Shanghai Palan DataRx Co. Ltd, Shanghai 200051, China.
Lu Y; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Pokaż więcej
Źródło :
Journal of comparative effectiveness research [J Comp Eff Res] 2020 Jan; Vol. 9 (2), pp. 93-102. Date of Electronic Publication: 2020 Jan 21.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*economics
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Crizotinib/*economics
Crizotinib/*therapeutic use
Lung Neoplasms/*drug therapy
Adult ; Aged ; Anaplastic Lymphoma Kinase ; Antineoplastic Agents/adverse effects ; China ; Cost-Benefit Analysis ; Crizotinib/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Models, Econometric ; Neoplasm Staging ; Progression-Free Survival ; Quality-Adjusted Life Years
Czasopismo naukowe
Tytuł :
Complete remission for 4 years with crizotinib in advanced ALK-positive non-small cell lung cancer after thoracostomy for empyema.
Autorzy :
Van Damme E; Faculty of Medicine, University of Ghent, Ghent, Belgium.
Kiselinova M; Department of Internal Medicine, University of Ghent, Ghent, Belgium.
Van Schoote E; Department of Pneumology, Sint-Elisabeth Hospital, Zottegem, Belgium.
Pokaż więcej
Źródło :
Tumori [Tumori] 2019 Dec; Vol. 105 (6), pp. NP35-NP37. Date of Electronic Publication: 2019 Apr 26.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Anaplastic Lymphoma Kinase/*genetics
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*genetics
Crizotinib/*therapeutic use
Lung Neoplasms/*drug therapy
Lung Neoplasms/*genetics
Protein Kinase Inhibitors/*therapeutic use
Adult ; Carcinoma, Non-Small-Cell Lung/complications ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Crizotinib/administration & dosage ; Crizotinib/adverse effects ; Empyema/complications ; Empyema/diagnosis ; Empyema/surgery ; Humans ; Lung Neoplasms/complications ; Lung Neoplasms/diagnosis ; Male ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Radiography, Thoracic ; Thoracostomy ; Tomography, X-Ray Computed ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Novel Crizotinib-GnRH Conjugates Revealed the Significance of Lysosomal Trapping in GnRH-Based Drug Delivery Systems.
Autorzy :
Murányi J; MTA-SE Pathobiochemistry Research Group, Tűzoltó St. 37-47, H1094 Budapest, Hungary.; Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University, H1094 Budapest, Hungary.
Varga A; MTA-SE Pathobiochemistry Research Group, Tűzoltó St. 37-47, H1094 Budapest, Hungary.
Gyulavári P; MTA-SE Pathobiochemistry Research Group, Tűzoltó St. 37-47, H1094 Budapest, Hungary.
Pénzes K; MTA-SE Pathobiochemistry Research Group, Tűzoltó St. 37-47, H1094 Budapest, Hungary.
Németh CE; Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University, H1094 Budapest, Hungary.
Csala M; Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University, H1094 Budapest, Hungary.
Pethő L; MTA-ELTE Research Group of Peptide Chemistry, Eötvös Loránd University, H1117 Budapest, Hungary.
Csámpai A; Institute of Chemistry, Eötvös Loránd University, H1117 Budapest, Hungary.
Halmos G; Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, H4032 Debrecen, Hungary.
Peták I; Oncompass Medicine Hungary Ltd., H1024 Budapest, Hungary.
Vályi-Nagy I; Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, H1097 Budapest, Hungary.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2019 Nov 08; Vol. 20 (22). Date of Electronic Publication: 2019 Nov 08.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Delivery Systems*
Crizotinib/*pharmacology
Gonadotropin-Releasing Hormone/*pharmacology
Lysosomes/*metabolism
Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Non-Small-Cell Lung/pathology ; Cell Line, Tumor ; Cell Membrane Permeability/drug effects ; Cell Survival ; Crizotinib/chemical synthesis ; Crizotinib/chemistry ; Drug Design ; Fibroblasts/metabolism ; Galectins/metabolism ; Gonadotropin-Releasing Hormone/chemical synthesis ; Gonadotropin-Releasing Hormone/chemistry ; Humans ; Hydrogen-Ion Concentration ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Models, Biological ; Proto-Oncogene Proteins c-met/antagonists & inhibitors ; Proto-Oncogene Proteins c-met/metabolism ; Receptors, LHRH/metabolism ; Skin/cytology
Czasopismo naukowe
Tytuł :
Successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease.
Autorzy :
Xie X; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, No. 151 Yanjiang Road, Guangzhou, 510120, Guangdong, People's Republic of China.
Guo B; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, No. 151 Yanjiang Road, Guangzhou, 510120, Guangdong, People's Republic of China.
Lin X; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, No. 151 Yanjiang Road, Guangzhou, 510120, Guangdong, People's Republic of China.
Qin Y; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, No. 151 Yanjiang Road, Guangzhou, 510120, Guangdong, People's Republic of China.
Ouyang M; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, No. 151 Yanjiang Road, Guangzhou, 510120, Guangdong, People's Republic of China.
Li S; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, No. 151 Yanjiang Road, Guangzhou, 510120, Guangdong, People's Republic of China.
Zhou C; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, No. 151 Yanjiang Road, Guangzhou, 510120, Guangdong, People's Republic of China. .
Pokaż więcej
Źródło :
Angiogenesis [Angiogenesis] 2019 Nov; Vol. 22 (4), pp. 477-479. Date of Electronic Publication: 2019 Jun 27.
Typ publikacji :
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Crizotinib*/administration & dosage
Crizotinib*/adverse effects
Lung Diseases, Interstitial*/chemically induced
Lung Diseases, Interstitial*/drug therapy
Lung Diseases, Interstitial*/pathology
Adenocarcinoma of Lung/*drug therapy
Adrenal Cortex Hormones/*administration & dosage
Bevacizumab/*administration & dosage
Lung Neoplasms/*drug therapy
Adenocarcinoma of Lung/pathology ; Female ; Humans ; Lung Neoplasms/pathology ; Middle Aged
Czasopismo naukowe
Tytuł :
Longitudinal health utilities, symptoms and toxicities in patients with ALK-rearranged lung cancer treated with tyrosine kinase inhibitors: a prospective real-world assessment.
Autorzy :
Tse, B. C.
Said, B. I.
Fan, Z. J.
Hueniken, K.
Patel, D.
Gill, G.
Liang, M.
Razooqi, M.
Brown, M. C.
Sacher, A. G.
Bradbury, P. A.
Shepherd, F. A.
Leighl, N. B.
Xu, W.
Howell, D.
Liu, G.
O'Kane, G.
Pokaż więcej
Źródło :
Current Oncology. 2020, Vol. 27 Issue 6, pe552-e559. 8p. 5 Charts, 2 Graphs.
Czasopismo naukowe
Tytuł :
Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report.
Autorzy :
Guisier F; Service de pneumologie, oncologie thoracique et soins intensifs respiratoires, CHU Charles Nicolle, Rouen, France. .; LITIS QuantIF EA4108, Normadie Univ, Rouen, France. .; INSERM CIC 1404, CHU Charles Nicolle, Rouen, France. .
Piton N; Service d'anatomie et cytologie pathologiques, CHU Charles Nicolle, Rouen, France.
Bellefleur M; Service de pneumologie, oncologie thoracique et soins intensifs respiratoires, CHU Charles Nicolle, Rouen, France.
Delberghe N; Service de pneumologie, oncologie thoracique et soins intensifs respiratoires, CHU Charles Nicolle, Rouen, France.
Avenel G; Service de rhumatologie, CHU Charles Nicolle, Rouen, France.
Angot E; Service d'anatomie et cytologie pathologiques, CHU Charles Nicolle, Rouen, France.
Vittecoq O; Service de rhumatologie, CHU Charles Nicolle, Rouen, France.
Ould-Slimane M; Service d'orthopédie et traumatologie, CHU Charles Nicolle, Rouen, France.
Morisse-Pradier H; Service de pneumologie, oncologie thoracique et soins intensifs respiratoires, CHU Charles Nicolle, Rouen, France.
Salaun M; Service de pneumologie, oncologie thoracique et soins intensifs respiratoires, CHU Charles Nicolle, Rouen, France.; LITIS QuantIF EA4108, Normadie Univ, Rouen, France.; INSERM CIC 1404, CHU Charles Nicolle, Rouen, France.
Thiberville L; Service de pneumologie, oncologie thoracique et soins intensifs respiratoires, CHU Charles Nicolle, Rouen, France.; LITIS QuantIF EA4108, Normadie Univ, Rouen, France.; INSERM CIC 1404, CHU Charles Nicolle, Rouen, France.
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2020 Jan 06; Vol. 20 (1), pp. 14. Date of Electronic Publication: 2020 Jan 06.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Anaplastic Lymphoma Kinase/*antagonists & inhibitors
Antineoplastic Agents/*adverse effects
Carcinoma, Non-Small-Cell Lung/*drug therapy
Crizotinib/*adverse effects
Lung Neoplasms/*drug therapy
Osteitis/*chemically induced
Protein Kinase Inhibitors/*adverse effects
Adult ; Anaplastic Lymphoma Kinase/genetics ; Antineoplastic Agents/therapeutic use ; Bone Neoplasms/diagnosis ; Bone Neoplasms/secondary ; Carcinoma, Non-Small-Cell Lung/complications ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Crizotinib/therapeutic use ; Female ; Humans ; Lung Neoplasms/complications ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Osteitis/diagnostic imaging ; Osteitis/pathology ; Protein Kinase Inhibitors/pharmacology ; Pyrimidines/pharmacology ; Sulfones/pharmacology ; Tomography, X-Ray Computed
Czasopismo naukowe
Tytuł :
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
Autorzy :
Moro-Sibilot D; Thoracic Oncology Unit, Grenoble-Alpes University Hospital, Grenoble; Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris. Electronic address: .
Cozic N; Department of Biostatistics and Epidemiology, Gustave Roussy Cancer Campus, INSERM U1018, ESP, Paris-Saclay and Paris-Sud Universities, Villejuif.
Pérol M; Department of Medical Oncology, Léon Bérard Cancer Centre, Lyon.
Mazières J; Pneumology Department, Toulouse University Hospital and Paul Sabatier University, Toulouse.
Otto J; Department of Medicine, Antoine Lacassagne Cancer Centre, Nice.
Souquet PJ; Department of Pneumology and Thoracic Oncology, Lyon Sud Hospital Center, Hospices Civils de Lyon, Pierre Bénite.
Bahleda R; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif.
Wislez M; Pneumology Department, Tenon Hospital, AP-HP and 'Pierre and Marie Curie' University, Paris.
Zalcman G; Thoracic Oncology Department-CIC INSERM 1425, Bichat University Hospital, AP-HP, Paris; Paris-Diderot University, Paris.
Guibert SD; Hematology Department, Pontchaillou, Rennes.
Barlési F; Multidisciplinary Oncology & Therapeutic Innovations Department, APHM and Aix Marseille University, INSERM, CNRS, CRCM, Marseille.
Mennecier B; Pneumology Department, Strasbourg University Hospital, Strasbourg.
Monnet I; Pneumology Department, CHIC Creteil, Créteil.
Sabatier R; Department of Medical Oncology, Inserm 1068, CNRS UMR7258, CRCM, Paoli-Calmettes Institute and Aix-Marseille University, Marseille.
Bota S; Pneumology Department, Charles Nicolle Hospital, Rouen University Hospital, Rouen.
Dubos C; Pneumology Department, François Baclesse Cancer Centre, Caen.
Verriele V; Anatomy and Pathological Cytologies Department, Paul Papin Cancer Centre, ICO, Angers.
Haddad V; Department of Tumour Biology, Léon Bérard Cancer Centre, Lyon.
Ferretti G; Radiology and Medical Imaging Department, Grenoble-Alpes University Hospital, Grenoble.
Cortot A; Department of Thoracic Oncology, Lille University Hospital and University of Lille, Lille.
De Fraipont F; Molecular Genetic Unit: Hereditary Diseases and Oncology, Grenoble-Alpes University Hospital, Grenoble.
Jimenez M; Research and Development UNICANCER, Paris.
Hoog-Labouret N; French National Cancer Institute, Boulogne-Billancourt.
Vassal G; Clinical Research Division, Gustave Roussy Cancer Campus, Villejuif, France.
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2019 Dec 01; Vol. 30 (12), pp. 1985-1991.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*drug therapy
Crizotinib/*administration & dosage
Protein-Tyrosine Kinases/*genetics
Proto-Oncogene Proteins/*genetics
Proto-Oncogene Proteins c-met/*genetics
Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Crizotinib/adverse effects ; Disease-Free Survival ; Female ; Gene Rearrangement/genetics ; Humans ; Male ; Middle Aged ; Molecular Targeted Therapy ; Mutation/genetics ; Oncogene Proteins, Fusion/genetics ; Progression-Free Survival ; Protein Kinase Inhibitors/administration & dosage
Czasopismo naukowe
Tytuł :
Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer.
Autorzy :
Deng H; Subject Hebei Provincial Department of Health, 20190683, PR China.
Li B; Subject Hebei Provincial Department of Health, 20190683, PR China.
Li L; Subject Hebei Provincial Department of Health, 20190683, PR China.
Peng J; Subject Hebei Provincial Department of Health, 20190683, PR China.
Lv T; Subject Hebei Provincial Department of Health, 20190683, PR China.
Liu Y; Subject Hebei Provincial Department of Health, 20190683, PR China. Electronic address: .
Ding C; Subject Hebei Provincial Department of Health, 20190683, PR China. Electronic address: .
Pokaż więcej
Źródło :
Pathology, research and practice [Pathol Res Pract] 2019 Dec; Vol. 215 (12), pp. 152695. Date of Electronic Publication: 2019 Oct 16.
Typ publikacji :
Journal Article
MeSH Terms :
Anaplastic Lymphoma Kinase/*antagonists & inhibitors
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Crizotinib/*therapeutic use
Lung Neoplasms/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Adult ; Aged ; Anaplastic Lymphoma Kinase/genetics ; Anaplastic Lymphoma Kinase/metabolism ; Antineoplastic Agents/adverse effects ; Brain Neoplasms/radiotherapy ; Brain Neoplasms/secondary ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/secondary ; China ; Cranial Irradiation ; Crizotinib/adverse effects ; Disease Progression ; Female ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Progression-Free Survival ; Protein Kinase Inhibitors/adverse effects ; Signal Transduction ; Time Factors
Czasopismo naukowe
Tytuł :
Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.
Autorzy :
Radaram B; Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Pisaneschi F; Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Rao Y; Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Yang P; Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Piwnica-Worms D; Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. Electronic address: .
Alauddin MM; Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2019 Nov 15; Vol. 182, pp. 111571. Date of Electronic Publication: 2019 Aug 09.
Typ publikacji :
Journal Article
MeSH Terms :
Anaplastic Lymphoma Kinase/*antagonists & inhibitors
Antineoplastic Agents/*pharmacology
Carbazoles/*pharmacology
Crizotinib/*pharmacology
Piperidines/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Pyrimidines/*pharmacology
Sulfones/*pharmacology
Anaplastic Lymphoma Kinase/metabolism ; Animals ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Carbazoles/chemical synthesis ; Carbazoles/chemistry ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Crizotinib/chemical synthesis ; Crizotinib/chemistry ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Fluorine Radioisotopes ; Humans ; Mice ; Molecular Structure ; Piperidines/chemical synthesis ; Piperidines/chemistry ; Positron-Emission Tomography ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Pyrimidines/chemical synthesis ; Pyrimidines/chemistry ; Radionuclide Imaging ; Structure-Activity Relationship ; Sulfones/chemical synthesis ; Sulfones/chemistry ; Tissue Distribution
Czasopismo naukowe
Tytuł :
Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
Autorzy :
Naito T; Department of Respiratory Medicine, Mitsui Memorial Hospital, Tokyo, Japan.
Shiraishi H; Department of Respiratory Medicine, Mitsui Memorial Hospital, Tokyo, Japan.
Fujiwara Y; Department of Respiratory Medicine, Mitsui Memorial Hospital, Tokyo, Japan.
Pokaż więcej
Źródło :
Japanese journal of clinical oncology [Jpn J Clin Oncol] 2021 Jan 01; Vol. 51 (1), pp. 37-44.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Mutation*
Anaplastic Lymphoma Kinase/*antagonists & inhibitors
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Central Nervous System Neoplasms/*secondary
Lactams, Macrocyclic/*therapeutic use
Lung Neoplasms/*drug therapy
Organophosphorus Compounds/*therapeutic use
Protein Kinase Inhibitors/*therapeutic use
Pyrimidines/*therapeutic use
Anaplastic Lymphoma Kinase/analysis ; Carcinoma, Non-Small-Cell Lung/enzymology ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Crizotinib/therapeutic use ; Drug Resistance, Neoplasm/genetics ; Humans ; Lung Neoplasms/enzymology ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology
Czasopismo naukowe
Tytuł :
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Autorzy :
Drilon A; Memorial Sloan Kettering Cancer Center, New York, NY, USA. .; Weill Cornell Medical College, New York, NY, USA. .
Clark JW; Massachusetts General Hospital, Boston, MA, USA.
Weiss J; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Ou SI; University of California Irvine School of Medicine, Orange, CA, USA.
Camidge DR; University of Colorado Cancer Center, Denver, CO, USA.
Solomon BJ; Peter MacCallum Cancer Centre, Melbourne, Australia.
Otterson GA; Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Villaruz LC; Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Riely GJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Heist RS; Massachusetts General Hospital, Boston, MA, USA.
Awad MM; Dana Farber Cancer Institute, Boston, MA, USA.
Shapiro GI; Dana Farber Cancer Institute, Boston, MA, USA.
Satouchi M; Hyogo Cancer Center, Akashi, Japan.
Hida T; Aichi Cancer Center, Nagoya, Japan.
Hayashi H; Department of Medicine, Kindai University, Osaka, Japan.
Murphy DA; Pfizer Oncology, La Jolla, CA, USA.
Wang SC; Pfizer Oncology, San Francisco, CA, USA.
Li S; Pfizer Oncology, La Jolla, CA, USA.
Usari T; Pfizer Oncology, Milan, Italy.
Wilner KD; Pfizer Oncology, La Jolla, CA, USA.
Paik PK; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Pokaż więcej
Źródło :
Nature medicine [Nat Med] 2020 Jan; Vol. 26 (1), pp. 47-51. Date of Electronic Publication: 2020 Jan 13.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Crizotinib/*therapeutic use
Exons/*genetics
Lung Neoplasms/*drug therapy
Mutation/*genetics
Proto-Oncogene Proteins c-met/*genetics
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/pharmacology ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Crizotinib/pharmacology ; Disease-Free Survival ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
Early Blood-based Liquid Biopsy in Patients with Treatment-naïve Metastatic Adenocarcinoma of the Lung: A Case Series.
Autorzy :
Peled M; Institute of Pulmonary Medicine, Sheba Medical Center, Tel Hashomer, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Bar J; Department of Radiation Oncology, Sheba Medical Center, Tel Hashomer, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Avni L; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel.
Chatterji S; Institute of Pulmonary Medicine, Sheba Medical Center, Tel Hashomer, Israel.
Somech D; Institute of Pulmonary Medicine, Sheba Medical Center, Tel Hashomer, Israel.
Dvir A; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel.
Soussan-Gutman L; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel.
Onn A; Institute of Pulmonary Medicine, Sheba Medical Center, Tel Hashomer, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pokaż więcej
Źródło :
The Israel Medical Association journal : IMAJ [Isr Med Assoc J] 2020 Dec; Vol. 22 (12), pp. 784-787.
Typ publikacji :
Journal Article
MeSH Terms :
Adenocarcinoma of Lung/*diagnosis
Lung Neoplasms/*diagnosis
Acrylamides/therapeutic use ; Adenocarcinoma of Lung/blood ; Adenocarcinoma of Lung/drug therapy ; Adenocarcinoma of Lung/genetics ; Aged ; Aged, 80 and over ; Aniline Compounds/therapeutic use ; Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor/blood ; Carbazoles/therapeutic use ; Carcinoma, Non-Small-Cell Lung/blood ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Crizotinib/therapeutic use ; DNA, Neoplasm/blood ; Female ; Genotyping Techniques ; Humans ; Lung Neoplasms/blood ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Male ; Middle Aged ; Piperidines/therapeutic use ; Prospective Studies
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies